Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Experimental evolution study using in vitro and ex vivo models to characterize an adapted phage variant; no animal infection efficacy data, clinical outcomes, or in vivo proof of concept reported.
Cross-species translational study with human observational data showing a novel non-linear association, but limited by lack of prospective design, mechanistic uncertainty, and authors' own call for validation in independent cohorts.
This is a mechanistic study combining transcriptomic analysis with in vivo and in vitro experiments in animal models and cell lines, demonstrating proof-of-concept for EGCG's antioxidant and anti-apoptotic effects in podocytes but providing no clinical trial evidence or human efficacy data.
Historical commentary confirming antidepressant-like effects of valproic acid in rodent models first demonstrated in the 1980s, supporting recent meta-analytic findings but not providing new primary evidence.
This is a narrative review synthesizing prior literature on S. suis serotype 2 virulence mechanisms; it raises questions and organizes existing knowledge rather than reporting new experimental evidence or clinical outcomes.
A mechanistic study in cell and transgenic mouse models showing FGF17 delivery reduces Aβ deposition and apoptosis with pathway confirmation, but lacking human efficacy data and powered clinical outcomes.
A controlled preclinical study in an animal AD model showing reversal of multiple network and molecular abnormalities with 40 Hz stimulation; sound design but limited to rodents and requires confirmation in humans.
Mechanistically-supported preclinical evidence in diet-induced obese mice demonstrates metabolic and inflammatory benefits with a putative pathway (kynurenine reduction), but lacks human efficacy data and comparative controls needed for strong or practice-changing classification.